10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

Reports from the conference

The following early reports from the conference are included thanks to

  • Genetic markers linked to early discontinuation of three antiretrovirals
  • Efavirenz lowers levels of darunavir given as 900/100 mg once daily with ritonavir
  • How much (or how little) ritonavir do you need to boost another PI?

Other reports in this issue are:

  • Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination
  • Interactions between ARVs and the antimalarials atovaquone and proguanil
  • Four weeks lopinavir/r to cover functional monotherapy when stopping HAART
  • Efavirenz-related studies: genetics, smoking and TDM
  • Atazanavir: a suitable case for TDM?
  • Raltegravir PK in blood plasma and the genital tract
  • A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission
  • Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding
  • Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children
  • Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents
  • Bioavailability of Thai generic lopinavir/ritonavir

It is disappointing that the abstracts from the virology-education meetings are not published online, and that only a selection of presentations from the meeting are available at:

A useful summary report of the drug-interaction studies presented at the meeting is available on the Liverpool University website (in the April 2009 news archive):

Links to other websites are current at date of posting but not maintained.